ADC Therapeutics

Switzerland
Malters, Lucerne, Switzerland, 1066

Company profile

ADC Therapeutics company profile

ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.

Business identity

Contact email
[email protected]
Phone number
+1 908-731-5556
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$50,000+
Founded
2011-01-01, Year

Headquarters

Postal code
1066
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
13
Total equity funding
$901.6M
Last funding
Post IPO Equity / $60M / 2025-10-13
Last equity funding
Post IPO Equity / $60M
Investors
8
Lead investors
4
Founders
1
Articles
296
Exited on
2020-05-14

Founders and investors

Founders

Christopher Martin

Lead investors

Auven TherapeuticsDeerfieldRedmile GroupTCG Crossover

Investors

4BIO CapitalAstraZenecaDeerfieldRedmile GroupTCG Crossover